Abstract:Abstract Long-lived species Homo sapiens have evolved robust protection mechanisms against cancer by repressing telomerase and maintaining short telomeres, thereby delaying the onset of the majority of cancer types until post-reproductive age. Indeed, telomerase is silent in most differentiated human cells, predominantly due to the transcriptional repression of its catalytic component telomerase reverse transcriptase (TERT) gene. The lack of telomerase/TERT expression leads to progressive telomere erosion in dividing human cells, whereas critically shortened telomere length induces a permanent growth arrest stage named replicative senescence. TERT/telomerase activation has been experimentally shown to be essential to cellular immortalization and malignant transformation by stabilizing telomere length and erasing the senescence barrier. Consistently, TERT expression/telomerase activity is detectable in up to 90% of human primary cancers. Compelling evidence has also accumulated that TERT contributes to cancer development and progression via multiple activities beyond its canonical telomere-lengthening function. Given these key roles of telomerase and TERT in oncogenesis, great efforts have been made to decipher mechanisms underlying telomerase activation and TERT induction. In the last two decades since the TERT gene and promoter were cloned, the derepression of the TERT gene has been shown to be achieved typically at a transcriptional level through dysregulation of oncogenic factors or signaling, post-transcriptional/translational regulation and genomic amplification. However, advances in high-throughput next-generation sequencing technologies have prompted a revolution in cancer genomics, which leads to the recent discovery that genomic alterations take center stage in activating the TERT gene. In this review article, we summarize critical mechanisms activating TERT transcription, with special emphases on the contribution of TERT promoter mutations and structural alterations at the TERT locus, and briefly discuss the underlying implications of these genomic events-driven TERT hyperactivity in cancer initiation/progression and potential clinical applications as well.

Inhibition of telomerase by targeting MAP kinase signaling.

Argininosuccinate Lyase Drives Activation of Mutant TERT Promoter in Glioblastomas

Transcriptional Regulation of Telomerase Activity

Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications

Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players

The regulations of telomerase reverse transcriptase (TERT) in cancer

Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer

Transforming Growth Factor β Suppresses Human Telomerase Reverse Transcriptase (hTERT) by Smad3 Interactions with c-Myc and the hTERT Gene

Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene

Targeting telomerase for cancer therapy

New Tumor Suppressor Cxxc Finger Protein 4 Inactivates Mitogen Activated Protein Kinase Signaling

Tumor-specific Activation of Human Telomerase Reverses Transcriptase Promoter Activity by Activating Enhancer-binding Protein-2β in Human Lung Cancer Cells

Transcriptional regulation mechanism and targeted cancer therapy of human telomerase reverse transcriptase promoter

Targeting telomerase for its advent in cancer therapeutics

Inhibition of telomerase limits the growth of human cancer cells

Human telomerase reverse transcriptase is a novel target of Hippo-YAP pathway

Feedback regulation of telomerase reverse transcriptase: new insight into the evolving field of telomerase in cancer

Ets2 Maintains Htert Gene Expression and Breast Cancer Cell Proliferation by Interacting with C-Myc.

Telomerase Reverse Transcriptase Promotes Epithelial–mesenchymal Transition and Stem Cell-Like Traits in Cancer Cells

hTERT promotes tumor progression by enhancing TSPAN13 expression in osteosarcoma cells

Epigenetic Regulation of the Human Telomerase Reverse Transciptase Gene: A Potential Therapeutic Target for the Treatment of Leukemia (Review)